Abstract
Mycoplasma pneumoniae (M.pneumoniae) is one of the predominant pathogenic bacteria causing community acquired pneumonia. An epidemic of M. pneumoniae infection occurs every three to seven years worldwide. It can cause a variety of clinical symptoms. Since 2000, macrolide-resistant M. pneumoniae strains have become increasingly common in many countries around the world and the drug resistance rate has reached as high as 100% in some area, which has posed a great threat to human health. This paper will review the status and mechanism of drug resistance in M. pneumoniae. Key words: Mycoplasma pneumoniae; Global drug resistance; Drug resistance mechanism
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
